|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Bhanvadia SK: Bladder cancer survivorship.
Curr Urol Rep. 19:1112018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anderson B: Bladder cancer: Overview and
management. Part 2: Muscle-invasive and metastatic bladder cancer.
Br J Nurs. 27 (Suppl):S8–S20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Woldu SL, Bagrodia A and Lotan Y:
Guideline of guidelines: Non-muscle-invasive bladder cancer. BJU
Int. 119:371–380. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
D Elia C, Pycha A, Folchini DM, Mian C,
Hanspeter E, Schwienbacher C, Vjaters E, Pycha A and Trenti E.:
Diagnostic predictive value of Xpert bladder cancer monitor in the
follow-up of patients affected by non-muscle invasive bladder
cancer. J Clin Pathol. 72:140–144. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Babjuk M, Burger M, Capoun O, Cohen D,
Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F,
Masson-Lecomte A, Mostafid AH, et al: European association of
urology guidelines on Non-muscle-invasive bladder cancer (Ta, T1,
and Carcinoma in situ). Eur Urol. 81:75–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hurle R, Casale P, Saita A, Colombo P,
Elefante GM, Lughezzani G, Fasulo V, Paciotti M, Domanico L,
Bevilacqua G, et al: Clinical performance of Xpert Bladder Cancer
(BC) Monitor, a mRNA-based urine test, in active surveillance (AS)
patients with recurrent non-muscle-invasive bladder cancer (NMIBC):
Results from the Bladder Cancer Italian Active Surveillance (BIAS)
project. World J Urol. 38:2215–2220. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matulewicz RS, DeLancey JO and Meeks JJ:
Cystoscopy. JAMA. 317:11872017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gezginci E, Iyigun E, Kibar Y and Bedir S:
Three distraction methods for pain reduction during cystoscopy: A
randomized controlled trial evaluating the effects on pain,
Anxiety, and satisfaction. J Endourol. 32:1078–1084. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kwon WA, Lee JW, Seo HK, Oh TH, Park SC,
Jeong HJ and Seo IY: Hand-holding during cystoscopy decreases
patient anxiety, pain, and dissatisfaction: A pilot randomized
controlled trial. Urol Int. 100:222–227. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Valenberg FJPV, Hiar AM, Wallace E, Bridge
JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK, et
al: Prospective validation of an mRNA-based urine test for
surveillance of patients with bladder cancer. Eur Urol. 75:853–860.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
14
|
Edgar R, Domrachev M and Lash AE: Gene
expression omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clough E, Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, et al: NCBI GEO: Archive for gene expression and
epigenomics data sets: 23-year update. Nucleic Acids Res.
52:D138–D144. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Zhang X, Du Y, Xiong W, Zhang X,
Zhang B and Shang P: High FSTL1 expression promotes bladder cancer
progression by enhancing tumor cell migration. Clin Transl Oncol.
28:265–276. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aizezi X, Silafu B, Ma Y, Wang Z, Li J and
Huang J: Analysis of IGFL2 gene expression and prognostic value in
bladder cancer based on TCGA database. Asia Pac J Clin Oncol.
22:129–139. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bilandzic M, Rainczuk A, Green E,
Fairweather N, Jobling TW, Plebanski M and Stephens AN: Keratin-14
(KRT14) positive leader cells mediate mesothelial clearance and
invasion by ovarian cancer cells. Cancers (Basel). 11:12282019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Verma A, Singh A, Singh MP, Nengroo MA,
Saini KK, Satrusal SR, Khan MA, Chaturvedi P, Sinha A, Meena S, et
al: EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC
peritoneal metastasis. Nat Commun. 13:73442022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang S, Gao P, Wang X, Duan L, He X and Qu
J: Clinical utility of keratin 14 expression measurement in
reflecting the tumor properties and prognosis in patients with
renal cell carcinoma: A study with long-term follow-up. Int Urol
Nephrol. 56:2045–2053. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Azhati B, Maolakuerban N, Ma T, Li X and
Rexiati M: Up-regulation of DRAM2 promotes tolerance of bladder
transitional cell carcinoma to gemcitabine. Arch Med Sci.
16:1207–1217. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tian S, Wang C, Zhao X, Xuan Y, Wei W,
Dong Y, Tao W, Zhang C, Cai T, Liu C, et al: A CEBPB/TYMP/GDF15
signaling axis mediates tumor growth and cisplatin resistance in
bladder cancer. Transl Oncol. 61:1025372025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsumoto R, Tsuda M, Yoshida K, Tanino M,
Kimura T, Nishihara H, Abe T, Shinohara N, Nonomura K and Tanaka S:
Aldo-keto reductase 1C1 induced by interleukin-1β mediates the
invasive potential and drug resistance of metastatic bladder cancer
cells. Sci Rep. 6:346252016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang P, Wang J, Yu Z, Lu J, Sun Z and
Chen Z: Redefining bladder cancer treatment: Innovations in
overcoming drug resistance and immune evasion. Front Immunol.
16:15378082025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abe T, Masuda T, Tobo T, Hashimoto M,
Nakano Y, Saito H, Ofuchi T, Ikehara T, Tsujimoto A, Nakano T, et
al: ZNF282 promotes colorectal cancer progression possibly via E2F1
activation. Cancer Sci. 117:90–104. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Wang Y, Wang J, Li L and Bi J:
Identification of a Prognosis-related risk signature for bladder
cancer to predict survival and immune landscapes. J Immunol Res.
2021:32363842021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Luo J, Liu Z, Liu X, Ma Y, Zhang
B, Chen Y, Li X, Feng Z, Yang N, et al: Identification of hub genes
in colorectal cancer based on weighted gene co-expression network
analysis and clinical data from The Cancer Genome Atlas. Biosci
Rep. 41:BSR202112802021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu Q, Zhang L, Deng Y and Tang L:
Identification of immune-related and autophagy-related genes for
the prediction of survival in bladder cancer. BMC Genom Data.
23:602022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chu PG, Lyda MH and Weiss LM: Cytokeratin
14 expression in epithelial neoplasms: A survey of 435 cases with
emphasis on its value in differentiating squamous cell carcinomas
from other epithelial tumours. Histopathology. 39:9–16. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Papafotiou G, Paraskevopoulou V, Vasilaki
E, Kanaki Z, Paschalidis N and Klinakis A: KRT14 marks a
subpopulation of bladder basal cells with pivotal role in
regeneration and tumorigenesis. Nat Commun. 7:119142016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheah MT, Chen JY, Sahoo D,
Contreras-Trujillo H, Volkmer AK, Scheeren FA, Volkmer JP and
Weissman IL: CD14-expressing cancer cells establish the
inflammatory and proliferative tumor microenvironment in bladder
cancer. Proc Natl Acad Sci USA. 112:4725–4730. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang
C, Kurtova AV, Willingham SB, Pazhanisamy SK, Contreras-Trujillo H,
Storm TA, et al: Three differentiation states risk-stratify bladder
cancer into distinct subtypes. Proc Natl Acad Sci USA.
109:2078–2083. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheung KJ, Padmanaban V, Silvestri V,
Schipper K, Cohen JD, Fairchild AN, Gorin MA, Verdone JE, Pienta
KJ, Bader JS and Ewald AJ: Polyclonal breast cancer metastases
arise from collective dissemination of keratin 14-expressing tumor
cell clusters. Proc Natl Acad Sci USA. 113:E854–E863. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheung KJ, Gabrielson E, Werb Z and Ewald
AJ: Collective invasion in breast cancer requires a conserved basal
epithelial program. Cell. 155:1639–1651. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lichtner RB, Julian JA, North SM, Glasser
SR and Nicolson GL: Coexpression of cytokeratins characteristic for
myoepithelial and luminal cell lineages in rat 13762NF mammary
adenocarcinoma tumors and their spontaneous metastases. Cancer Res.
51:5943–5950. 1991.PubMed/NCBI
|
|
37
|
Gordon LA, Mulligan KT, Maxwell-Jones H,
Adams M, Walker RA and Jones JL: Breast cell invasive potential
relates to the myoepithelial phenotype. Int J Cancer. 106:8–16.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Petrocca F, Altschuler G, Tan SM, Mendillo
ML, Yan H, Jerry DJ, Kung AL, Hide W, Ince TA and Lieberman J: A
genome-wide siRNA screen identifies proteasome addiction as a
vulnerability of basal-like triple-negative breast cancer cells.
Cancer Cell. 24:182–196. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hossein Zadeh R, Hossein Zadeh R,
Hajimoradi M, Islampanah M, Zarimeidani F, Rahmati R, Ahmadinia M,
Bahrami N, Mohamadnia A, Shafaghi S and Nazari E: Identification of
diagnostic and prognostic biomarkers in lung adenocarcinoma through
integrated bioinformatics analysis and real time PCR validation.
Sci Rep. 16:66792026. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dong J, Kong L, Wang S, Xia M, Zhang Y, Wu
J, Yang F, Zuo S and Wei J: Oncolytic adenovirus encoding
apolipoprotein A1 suppresses metastasis of triple-negative breast
cancer in mice. J Exp Clin Cancer Res. 43:1022024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu S, Liu T, Yang C, Mou Z, Zou L and
Jiang H: Cytoskeletal protein KRT14 governs cisplatin resistance by
modulating eIF4H-dependent ACOX2 translation and lipid metabolism
in bladder cancer. Cell Death Dis. 17:1342025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu Z, Weng T, Cheng M, Lei T, Xiao D,
Deng Q and Wu T: KRT14 knockdown reduces cisplatin resistance by
lowering LRP11 expression levels in cisplatin-resistant ovarian
cancer cell lines. Transl Cancer Res. 14:1786–1798. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Q, Deng Y, Yu F and Liu Z: The
E2F1/SBK1 axis activates the Notch signaling pathway to accelerate
the malignant progression of breast cancer. Naunyn Schmiedebergs
Arch Pharmacol. 398:16045–16058. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han S, Lin M, Wu L, Lin X, Chen M, Hu C,
Bao A, Fang Z and Zhu F: E2F1 modulates RCCD1 expression to
participate in the initiation and progression of EMT in colorectal
cancer. Pathol Res Pract. 260:1554292024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhuo S, Yang L, Chen Z, Chen S, Yang S,
Chen T, Wu WS, Wang K and Yang K: Druggable target ATAD2 enhances
the malignant progression and cooperates with E2F1 to up-regulate
PDK1 expression in glioma. Genes Dis. 13:1018102025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Su M, Chen W, Luo J, Li X, Ye D, Han D and
Fu G: E2F1-induced transcriptional activation of MAL2 inhibits
sunitinib sensitivity and promotes the malignant progression of
bladder cancer. J Chemother. 1-12:2025.doi:
10.1080/1120009X.2025.2561275 (Epub ahead of print). PubMed/NCBI
|
|
47
|
Zhou F, Deng Z, Shen D, Lu M, Li M, Yu J,
Xiao Y, Wang G, Qian K, Ju L and Wang X: DLGAP5 triggers
proliferation and metastasis of bladder cancer by stabilizing E2F1
via USP11. Oncogene. 43:594–607. 2024. View Article : Google Scholar : PubMed/NCBI
|
